JP7775186B2 - アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態 - Google Patents

アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Info

Publication number
JP7775186B2
JP7775186B2 JP2022508779A JP2022508779A JP7775186B2 JP 7775186 B2 JP7775186 B2 JP 7775186B2 JP 2022508779 A JP2022508779 A JP 2022508779A JP 2022508779 A JP2022508779 A JP 2022508779A JP 7775186 B2 JP7775186 B2 JP 7775186B2
Authority
JP
Japan
Prior art keywords
compound
crystalline
salt
succinate salt
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022508779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544272A (ja
JP2022544272A5 (https=
Inventor
メデンドープ，クレア
マザイク，デブラ
ウィルキー，ゴードン
ウェートジグ，ジョシュア・ディー
ハインリック，ブライアン
マッキーカーン，ローレン
シーゲル，ドミニク
オーマー，ハラルド
ジョンストン，スティーブン・シー
Original Assignee
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2022544272A publication Critical patent/JP2022544272A/ja
Publication of JP2022544272A5 publication Critical patent/JP2022544272A5/ja
Priority to JP2025113638A priority Critical patent/JP2025148406A/ja
Application granted granted Critical
Publication of JP7775186B2 publication Critical patent/JP7775186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022508779A 2019-08-13 2020-08-12 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態 Active JP7775186B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113638A JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
US62/885,977 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113638A Division JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Publications (3)

Publication Number Publication Date
JP2022544272A JP2022544272A (ja) 2022-10-17
JP2022544272A5 JP2022544272A5 (https=) 2023-08-21
JP7775186B2 true JP7775186B2 (ja) 2025-11-25

Family

ID=72193669

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022508779A Active JP7775186B2 (ja) 2019-08-13 2020-08-12 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
JP2025113638A Pending JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025113638A Pending JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Country Status (14)

Country Link
US (1) US20220281879A1 (https=)
EP (1) EP4013757A1 (https=)
JP (2) JP7775186B2 (https=)
KR (1) KR20220052955A (https=)
CN (2) CN119638704A (https=)
BR (1) BR112022002597A2 (https=)
CA (1) CA3146701A1 (https=)
CO (1) CO2022001450A2 (https=)
IL (1) IL290482A (https=)
JO (1) JOP20220014A1 (https=)
MX (2) MX2022001741A (https=)
TW (1) TWI870440B (https=)
UA (1) UA130650C2 (https=)
WO (1) WO2021030386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311889B (zh) * 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513781A (ja) 2016-04-15 2019-05-30 ブループリント メディシンズ コーポレイション アクチビン受容体様キナーゼの阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513781A (ja) 2016-04-15 2019-05-30 ブループリント メディシンズ コーポレイション アクチビン受容体様キナーゼの阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARM TECH JAPAN，2002年，Vol.18, No.10，p.1629-1644

Also Published As

Publication number Publication date
JP2022544272A (ja) 2022-10-17
CN114222745A (zh) 2022-03-22
BR112022002597A2 (pt) 2022-07-05
CN114222745B (zh) 2025-03-25
CA3146701A1 (en) 2021-02-18
WO2021030386A1 (en) 2021-02-18
CO2022001450A2 (es) 2022-05-31
CN119638704A (zh) 2025-03-18
AU2020328534A1 (en) 2022-03-17
JP2025148406A (ja) 2025-10-07
EP4013757A1 (en) 2022-06-22
IL290482A (en) 2022-04-01
KR20220052955A (ko) 2022-04-28
TWI870440B (zh) 2025-01-21
JOP20220014A1 (ar) 2023-01-30
MX2024014312A (es) 2024-12-06
TW202120509A (zh) 2021-06-01
UA130650C2 (uk) 2026-04-08
US20220281879A1 (en) 2022-09-08
MX2022001741A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
JP7775186B2 (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
JP6317320B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
US9012641B2 (en) Crystalline forms of Prasugrel salts
JP7843116B2 (ja) ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態
WO2023138681A1 (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
WO2025149547A1 (en) New solid forms of n-[(1s,2e)-1-cyclopropyl-3-(methanesulfonyl)prop-2-en-1-yl]-2- (1,1-difluoroethyl)-4- phenoxypyrimidine-5-carboxamide
EP4438600A1 (en) Compound used as kinase inhibitor and use thereof
AU2020328534B2 (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
US10561667B2 (en) Orbit azine-fumarate, hydrate, crystal form and preparation method therefor
JP7356496B2 (ja) Ｌｔａ４ｈ阻害剤の結晶形態
HK40069001A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
HK40117473A (zh) 活化素受体样激酶抑制剂的盐和晶体形式
HK40069001B (zh) 活化素受体样激酶抑制剂的盐和晶体形式
EP1904459A1 (en) New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide
CN121241043A (zh) 埃维酰胺的晶型
WO2016081538A1 (en) Solid state forms of ceritinib and salts thereof
CN120344508A (zh) 苯并恶嗪酮类化合物的结晶及其制备
JP2023524622A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体
CN116514796A (zh) 3CLpro蛋白酶抑制剂的盐、晶型及其制备方法
JP2022515196A (ja) プロテインキナーゼ活性を阻害するためのアミノピリミジン系化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251112

R150 Certificate of patent or registration of utility model

Ref document number: 7775186

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150